Third in line: Editas says it may partner up on commercialization of sickle cell gene therapy

Zachary Brennan

Senior Editor

Editas Medicine continues to churn along in a solid third place in the race against bluebird bio, and partners Vertex and CRISPR to commercialize the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Third in line: Editas says it may partner up on commercialization of sickle cell gene therapy

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lexicon ends commercial work to focus on R&D

Are programs with compounded GLP-1s safe for your population?

Third in line: Ed­i­tas says it may part­ner up on com­mer­cial­iza­tion of sick­le cell gene ther­a­py

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Lex­i­con ends com­mer­cial work to fo­cus on R&D

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Third in line: Editas says it may partner up on commercialization of sickle cell gene therapy

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lexicon ends commercial work to focus on R&D

Are programs with compounded GLP-1s safe for your population?